BPG is committed to discovery and dissemination of knowledge
Homepage
Online Submission
Number of total visits
2399465
Number of visits today
487
Number of downloads
1571604
MEMBERSHIP
Cited by in F6Publishing
Number
Citing Articles
1
European Association for the Study of the Liver . Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018.J Hepatol . 2018;69 :461-511.29650333 DOI: 10.1016/j.jhep.2018.03.026 ] [ Cited by in Crossref: 905] [ Cited by in F6Publishing: 751 ] [ Article Influence: 226.3 ] [ Reference Citation Analysis ]
2
Wuerth K , Magel T, Conway B. Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C. Future Virology 2019;14 :715-27. [DOI: 10.2217/fvl-2019-0104 ] [ Reference Citation Analysis ]
3
Tse CS , Yang JD , Mousa OY , Nelson KM , Pungpapong S , Keaveny A , Aqel BA , Vargas H , Dickson RC , Watt K , Gores GJ , Roberts LR , Leise MD . Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplant Direct 2021;7 :e635. [PMID: 33324740 DOI: 10.1097/TXD.0000000000001049 ] [ Reference Citation Analysis ]
4
Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 [PMID: 29962815 DOI: 10.3748/wjg.v24.i24.2582 ] [ Cited by in CrossRef: 31 ] [ Cited by in F6Publishing: 30 ] [ Article Influence: 7.8 ] [ Reference Citation Analysis ]
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA California Corporate Number: 3537345
